Molecular Mechanism of Nishamalaki as Rasayana in Diabetes Mellitus

Abstract

Diabetes mellitus, a chronic non-communicable disorder, is on the rise in developing countries. In Ayurveda, a similar condition called Madhumeha is attributed to Dhatu kshaya (Emaciation) and Dosha avarana (occlusion of humoral factors). Rasayana therapy, involving herbal formulations like Nishamalaki, is recommended to strengthen the body's major structural components (dhatus), boost immunity, and promote longevity. Nishamalaki, a combination of Haridra (Curcuma longa Linn.) and Amalaki (Phyllantus emblica Linn.), exhibits antioxidant, anti-inflammatory, and lipid-reducing properties. It holds potential as a preventive measure to enhance the Quality of Life. The aim of this study was to validate the rejuvenation property of Nishamalaki in Diabetes mellitus using an insilico approach. Through tools such as SwissADME, SwissTargetPrediction, and Therapeutic Target Database (TTD), bioavailable components of Nishamalaki and Diabetes were analyzed, and a network was created using CytoScape. The results of the study identified two key compounds, Ellagic acid and Corilagin, which significantly modulate IGF1R and PTPN1, respectively, in Diabetes mellitus. These findings offer valuable insights into the potential therapeutic benefits of Nishamalaki in managing Diabetes mellitus and warrant further research and exploration in this area.